| Characteristics | n (%) |
|---|---|
| Recipient/donor age; median (range) | 50 (16-73)/39 (14-75) |
| Recipient/donor male sex | 85 (56)/85 (56) |
| Male receptor/Female donor | 37 (24) |
| Hematological disease | |
| AML / MDS | 63 (42)/19 (13) |
| HL / NHL | 22 (15)/24 (16) |
| ALL | 9 (6) |
| CMML | 5 (3) |
| Others | 4 (5) |
| Previous treatments ≥2 | 93 (61) |
| Previous autologous transplantation | 35 (23) |
| Previous allogenic transplantation | 13 (8) |
| Disease risk index ≥ high and very high | 27 (18) |
| Sorror, n (%) >3 | 44 (29) |
| Conditioning | |
| Myeloablative | 35 (23) |
| Flu (150mg/m2) + Bu (9,6mg/Kg) + Thio (10mg/Kg) | 29 (19) |
| Flu(150mg/m2)+Bu (9,6 mg/kg) + Cy(29mg/kg) | 6 (4) |
| Reduced intensity | 112 (73) |
| Flu (150 mg/m2) + Bu (3,2 ó 6,4mg/Kg) + Cy (29mg/Kg) | 99 (65) |
| Flu (150 mg/m2) + TBI (2Gy) + Cy (29 mg/kg) | 5 (3) |
| Flu(150mg/m2)+Bu(6,4mg/kg)+Thio(10mg/kg) | 8 (5) |
| Sequential | 5 (4) |
| GVHD prophylaxis | |
| Tacro + MMF + Cy | 148 (98) |
| CsA + MMF + Cy | 3 (2) |
| CD34 + x108 infused dose, median (range) | 6,26 (2.59-9,34) |
| Graft source: Peripheral blood | 148 (98) |
| Median follow up months, n (range) | 35 (9-87) |
| Overall Survival (OS) 2 years | 66% |
| PFS 2 years | 60% |
| NRM day 100 / 1 year | 14% / 24% |
| Cumulative incidence of aGVHD II-IV day 180 | 57% |
| Cumulative incidence of aGVHD III-IV day 180 | 13% |
| GRFS (Graft versus host-free relapse-free survival) 2 years | 49% |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.